Health care biotech companies by P/B ratio
Share price divided by book value per share: what the market pays for each dollar of shareholders' equity on the balance sheet.
Biogen has the lowest figure of the 18 health care biotech companies ranked by P/B ratio, at 1.9, followed by Vaxcyte (3.5) and Neurocrine Biosciences (4.1). Figures as of 20 Nov 2026, 00:11 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 18
- Lowest
- Biogen1.9
- Median
- 8.7
- Combined market value
- AED 3.04T
- Countries
- 5
- Not ranked
- 6no P/B ratio on file
Market values as of .
All countries▾
Health Care▾
Biotech▾
| # | Company | P/B ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | BiogenBIIB · Health Care | 1.9 | AED 134.2B | AED 907.66 | 1.70% down | 49% up | ||
| 2 | VaxcytePCVX · Health Care | 3.5 | AED 33.9B | AED 214.34 | 0.27% down | 23% up | ||
| 3 | Neurocrine BiosciencesNBIX · Health Care | 4.1 | AED 58.2B | AED 575.12 | 3.85% down | 17% up | ||
| 4 | RepligenRGEN · Health Care | 4.6 | AED 40B | AED 625.44 | 1.38% down | 12% up | ||
| 5 | Bio-TechneTECH · Health Care | 5.3 | AED 41.9B | AED 267.01 | 0.07% down | 24% up | ||
| 6 | Kymera TherapeuticsKYMR · Health Care | 6.3 | AED 37.4B | AED 438.50 | 1.44% down | 87% up | ||
| 7 | Krystal BiotechKRYS · Health Care | 6.5 | AED 34.4B | AED 1,159.94 | 0.15% up | 54% up | ||
| 8 | CG OncologyCGON · Health Care | 7.4 | AED 26.9B | AED 300.80 | 2.38% up | 97% up | ||
| 9 | Twist BioscienceTWST · Health Care | 8.5 | AED 28B | AED 409.96 | 4.07% down | 346% up | ||
| 10 | ExelixisEXEL · Health Care | 8.8 | AED 59B | AED 241.78 | 3.60% down | 63% up | ||
| 11 | ImmunovantIMVT · Health Care | 10.2 | AED 24.7B | AED 119.44 | 1.96% down | 46% up | ||
| 12 | ModernaMRNA · Health Care | 11.8 | AED 296.2B | AED 732.10 | 1.29% up | 780% up | ||
| 13 | Revolution MedicinesRVMD · Health Care | 14.4 | AED 126.7B | AED 585.55 | 0.24% down | 129% up | ||
| 14 | Gilead SciencesGILD · Health Care | 15.8 | AED 758.6B | AED 611.63 | 1.45% down | 35% up | ||
| 15 | AmgenAMGN · Health Care | 16.5 | AED 871.8B | AED 1,611.70 | 1.14% down | 32% up | ||
| 16 | Adaptive BiotechnologiesADPT · Health Care | 25.7 | AED 16.7B | AED 103.02 | 1.44% down | 74% up | ||
| 17 | Scholar Rock HoldingSRRK · Health Care | 36.4 | AED 22.6B | AED 185.00 | 4.94% up | 26% up | ||
| 18 | Kodiak SciencesKOD · Health Care | 499 | AED 23.5B | AED 359.57 | 0.09% up | 399% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 3.6728 AED). 6 companies have no P/B ratio on file and are not ranked here.
Questions and answers
Which health care biotech companies have the lowest P/B ratio?
Biogen (1.9), Vaxcyte (3.5) and Neurocrine Biosciences (4.1) have the lowest P/B ratio of the 18 health care biotech companies ranked here as of 20 Nov 2026, 00:11 UTC.
How many health care biotech companies are in this ranking?
18 are ranked by P/B ratio. 6 more have no P/B ratio on file and are left out rather than ranked at zero.
What are these health care biotech companies worth together?
The 18 health care biotech companies ranked by P/B ratio have a combined market value of AED 3.04T as of 20 Nov 2026, 00:11 UTC.
What does ranking by P/B ratio measure?
Share price divided by book value per share: what the market pays for each dollar of shareholders' equity on the balance sheet.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Piotroski F-score: the nine tests and what they show
The Piotroski F-score is a 0–9 count of simple accounting tests a company passes: four on profitability, three on debt, liquidity and share issuance, two on operating efficiency. Joseph Piotroski's 2000 paper found that among cheap, high book-to-market stocks, high scorers went on to beat low scorers. It is a screen of financial health, not a valuation.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Health care biotech companies by P/B ratio”, data as of 20 November 2026. https://funkfolio.com/companies/category/biotech?sector=health-care&by=pb-ratio
Underlying data: Yahoo Finance; SEC EDGAR.